Sanger Institute clinical analysis spin-out goes from strength to strength
Congenica, a leading provider of clinical genome analysis technology, has raised £8m ($10m) in its Series B financing round. Based on the Wellcome Genome Campus, the company was founded in 2014 by Sanger Institute researchers Dr Matt Hurles and Dr Richard Durbin to build on the pioneering work of the Deciphering Developmental Disorders (DDD) project.
Congenica provides personalised medicine through an online platform called SapientiaTM that highlights potential disease-causing variants in a patient’s genome and links these to observed symptoms and supporting research literature. The technology has been adopted in a number of important markets, including the UK, China, US and other EU countries. It has been validated by leading independent institutes and clinicians, including Genomics England Ltd under the UK 100K Genomes Project.
“Congenica is a great example of how world-leading scientific research from the Wellcome Trust Sanger Institute, with investment in continued technological advancement and commercialisation, can be translated into products and services that have an impact on human health and society.”
Dr Martin Dougherty, COO, of the Wellcome Trust Sanger Institute and the Wellcome Genome Campus
The company will use the Series B investment from to sustain the commercial rollout of its SapientiaTM clinical genome analysis platform, by accelerating international growth and expanding customer support. It will also invest in further product development and innovation.
“Congenica’s vision is to ensure that advances in genomics bring benefits to patients and healthcare delivery. Our goal is to be the international leader in data solutions for rapid and accurate diagnosis of rare and genetic disease. This financing will enable the exceptional work of the Congenica team to realise our next steps in product development, international expansion, and in supporting our growing user base.”
Tom Weaver, CEO at Congenica
Congenica recently announced the appointment of US-based Chief Business Officer Dr Shikha O’Brien, who will be instrumental in driving growth in international clinical diagnostics markets, as well with global pharmaceutical discovery and development partners.
The Series B funding has been provided by existing investors Cambridge Innovation Capital plc (CIC) and Amadeus Capital Partners (Amadeus), along with and Parkwalk Advisors (Parkwalk). In 2015, Congenica raised £2.2 Million in a series A financing, following a seed financing round of £500K in 2014.
“Having supported Congenica from its early stages, we have seen the company grow and achieve a number of important milestones. Located in the world-leading Cambridge cluster, Congenica has demonstrated its potential both in the UK and more widely, attracting a range of customers and winning accolades through industry awards. We remain convinced of the global potential of the Sapientia technology in a range of applications.”
Robert Tansley, Healthcare Investment Director at CIC
“Amadeus is known for investing in game-changing technologies and we strongly believe that Congenica’s genome-based diagnostics will have a profound impact on healthcare. Its data platform offers a truly personalised medicine solution, utilising patient-derived genomics data and providing the best diagnostic performance in the industry. We are pleased to continue to be part of Congenica’s journey.”
Hermann Hauser, Co-Founder and Partner, Amadeus Capital Partners
Following its investment, Alastair Kilgour at Parkwalk will join Congenica’s Board. Commenting on its decision to invest in the Series B he said
“Congenica is well positioned to provide key analytical components in the drive towards personalised, genomics-based medicine. The standard-setting efforts in genomics by the UK NHS and Genomics England provide an indicative framework for future success.”
Alastair Kilgour at Parkwalk